LifeMD and Medifast to create weight-management program that includes GLP-1 drugs
By Ciara Linnane
Medifast's stock slides 8% after company says it will scrap quarterly dividend to invest in program
LifeMD Inc., a virtual primary care provider, said Wednesday it's teaming up with Medifast Inc. (MED) to create a clinically supported weight management program that will include the new class of weight-loss drugs called GLP-1 receptor agonists.
Baltimore-based Medifast is a wellness company known for its habit-based and coach-guided lifestyle service Optavia.
The news sent both stocks sharply higher in premarket trade, but they quickly erased those gains to trade lower after Medifast disclosed that it will scrap its quarterly dividend to free up funds to invest in the program and in other growth and technology initiatives.
The GLP-1 drugs developed by Eli Lilly & Co. (LLY) and Denmark's Novo Nordisk (NVO) (DK:NOVO.B) are named after a gut hormone that they mimic to control appetite and blood sugar. They have become highly popular in the U.S. and have even seen shortages in the past year.
For more, read: Eli Lilly's Mounjaro three times more effective than Ozempic for weight loss, real-world study finds
LifeMD (LFMD) said the move will give it access to a market that's expected to reach $100 billion by 2030.
The partners will offer a program that includes one-on-one Optavia Coach support, proven plans and scientifically developed products, a proprietary Habits of Health (R) Transformational System, as well as community support.
Medifast has agreed to invest $20 million in LifeMD, including buying $10 million of its stock and will stop paying its quarterly dividend.
"This is intended to improve customer acquisition and customer experience, which the company expects will generate higher long-term stockholder returns, as well as allow for stock repurchases when management and the Board deem it appropriate," Medifast said in a statement.
The companies will hold a conference call at 10 a.m. Eastern to discuss the agreement.
LifeMD's stock was last down 5%, while Medifast was down 10%. The S&P 500 was up 0.1%.
-Ciara Linnane
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
12-13-23 1028ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
After Earnings, Is AT&T Stock a Buy, a Sell, or Fairly Valued?
-
Mastercard Earnings: A Stable Environment Highlights the Firm’s Strengths
-
Pfizer Earnings: Solid Results Supported by Steady Tracking Toward $4 Billion In Cost Cuts
-
10 Top-Performing Dividend Stocks
-
Starbucks Earnings: Not a Lot to Like About Results as Global Traffic Sputters
-
CVS Earnings: Weak Medicare Advantage Profits Cut Into 2024 Outlook
-
Amazon Earnings: AWS Growth Accelerates and Profit Margins Improve
-
SiriusXM Earnings: Decent Results With Plan for Technology and Content Investment to Drive Growth